SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person [*] Bartram Richard		* 1	2. Issuer Name and Ticker or Trading Symbol <u>Esperion Therapeutics, Inc.</u> [ESPR]		tionship of Reporting Per all applicable) Director	son(s) to Issuer 10% Owner	
		(1.4:-1-11-)	3. Date of Earliest Transaction (Month/Day/Year)		Officer (give title below)	Other (specify below)	
(Last)	(First)	(Middle)			Chief Einensiel	Officer	
C/O ESPERION THERAPEUTICS, INC.		S, INC.	01/02/2020		Chief Financial Officer		
3891 RANCHEI	RO DRIVE, SUITI	E 150					
P			4. If Amendment, Date of Original Filed (Month/Day/Year)		idual or Joint/Group Filin	g (Check Applicable	
(Street)				Line)			
· · ·	M	40100		X	Form filed by One Rep	orting Person	
ANN ARBOR	MI	48108			Form filed by More tha Person	n One Reporting	
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities A Disposed Of (5)			Securities Beneficially	(I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	01/02/2020		Α		7,525 ⁽¹⁾	Α	\$0.00	18,673	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$61.34	01/02/2020		A		33,900		(1)	01/02/2020	Common Stock	33,900	\$0.00	33,900	D	

Explanation of Responses:

1. The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020.

/s/ Richard B. Bartram

01/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.